NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
SN BioScience
Hoffmann-La Roche
Incyte Corporation
Incyte Corporation
TransThera Sciences (Nanjing), Inc.
Alliance for Clinical Trials in Oncology
Cyteir Therapeutics, Inc.
BeiGene
Sellas Life Sciences Group
Vincerx Pharma, Inc.
Mundipharma Research Limited
Xencor, Inc.
Cancer Research and Biostatistics Clinical Trials Consortium
TransThera Sciences (Nanjing), Inc.
Exelixis
HiberCell, Inc.
National Cancer Institute (NCI)
MacroGenics
Syros Pharmaceuticals
Massachusetts General Hospital
Eastern Cooperative Oncology Group
Fate Therapeutics
Xencor, Inc.
SWOG Cancer Research Network
Xencor, Inc.
Incyte Corporation
Hoffmann-La Roche
Novartis
AbbVie
AbbVie
Incyte Corporation
Gilead Sciences
Institut Bergonié
Incyte Corporation
AstraZeneca
Abramson Cancer Center at Penn Medicine
MedImmune LLC
University of Wisconsin, Madison
Daiichi Sankyo
Swiss Cancer Institute
Pfizer
Butler Hospital
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
University of Kansas Medical Center
Beth Israel Deaconess Medical Center
Wake Forest University Health Sciences
Roswell Park Cancer Institute
Mayo Clinic